Treatment of Schizophrenia with Aripiprazole. A one year open-label study examining an ultraslow switchover regime to minimise relapse and withdrawal symptoms.

Associate Professor Krishna Vaddadi0 个研究点目标入组 40 人开始时间: 2005年9月14日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Patients who are outpatients (private or public) attending southern health facility and have a well established diagnosis of schizophrenia (DSM-IV diagnosis criteria), who report side effects on their existing medication, who have not fully responded to their current therapy, who in the clinicians opinion, would benefit from Aripiprazole, who are able to comprehend what is happening to them and able to give informed consent, who can speak a reasonable level of English, and where completing rating scales with adequate information is not a practical problem.

•Patients who want to become pregnant during the study period, with alcohol dependence, with acquired brain injury associated with schizophrenia, who are on too complex medication regimes which would be difficult to change, who have previously been treated with Aripiprazole, who are on very high doses of clozapine in (>500mg/day), on very high doses of injectable Zuclopenthixol Decanoate (>200mg/fortnight), with a past history of severe violence/suicidal risk, who are generally non-compliant with oral medication, who have poor social supports and are very unreliable with appointments, and patients who are very stable on their current antipsychotic medication, but want to change to Aripiprazole simply because it is a new drug, their friend got better or, someone told them it is a good idea.

发起方

Associate Professor Krishna Vaddadi